Verrica raises ~$50M in PIPE to retire OrbiMed debt, extend runway into mid-2027

Verrica Pharmaceuticals Inc.

Gross proceeds of ~$50M from sale of 6.5M shares, 5.3M pre-funded warrants, and 2.95M Series C warrants.
$35M of net proceeds to fully repay OrbiMed credit facility ($50M drawn); remaining for working capital.
Cash runway extended into mid-2027; Q3 2025 cash balance was $21.1M.
Caligan Partners anchors financing, gets right to designate a Class I board member post-closing.
Series C warrants exercisable at $6.315/share, expire 5 years from close; pre-funded at $0.0001/share.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Verrica Pharmaceuticals Inc. issued pre-funded warrants to purchase 5,305,164 shares of Common Stock of warrant to certain institutional investors and other accredited investors for Purchase Price minus $0.0001 per Pre-Funded Warrant.

Security: warrant
Shares: pre-funded warrants to purchase 5,305,164 shares of Common Stock
Purchaser: certain institutional investors and other accredited investors
Consideration: Purchase Price minus $0.0001 per Pre-Funded Warrant

Exact text from the filing

to the Purchasers in a private placement transaction (the “ Private Placement ”) an aggregate of (i) 6,499,826 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), (ii) with respect to certain Purchasers, pre-funded warrants to purchase 5,305,164 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares and

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Verrica Pharmaceuticals Inc. issued Series C warrants to purchase 2,951,241 shares of Common Stock of warrant to institutional investors and other accredited investors for $4.24125 per share and accompanying Series C Warrant.

Security: warrant
Shares: Series C warrants to purchase 2,951,241 shares of Common Stock
Purchaser: institutional investors and other accredited investors
Consideration: $4.24125 per share and accompanying Series C Warrant

Exact text from the filing

Series C warrants to purchase 2,951,241 shares of Common Stock (the “ Series C Warrants ”). The purchase price per share of Common Stock and accompanying Series C Warrant is $4.24125 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants and accompanying Series C Warrant is the Purchase Price minus $0.0001 per Pre-Funded Warrant.

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Verrica Pharmaceuticals Inc. issued 6,499,826 shares of common stock to institutional investors and other accredited investors for $4.24125 per share.

Security: common stock
Shares: 6,499,826 shares
Purchaser: institutional investors and other accredited investors
Consideration: $4.24125 per share

Exact text from the filing

Series C warrants to purchase 2,951,241 shares of Common Stock (the “ Series C Warrants ”). The purchase price per share of Common Stock and accompanying Series C Warrant is $4.24125 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants and accompanying Series C Warrant is the Purchase Price minus $0.0001 per Pre-Funded Warrant.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Verrica Pharmaceuticals Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $4.24115 million (effective 2025-11-23).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $4.24115 million
Effective: 2025-11-23

Exact text from the filing

On November 23, 2025, Verrica Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement with certain institutional investors

View on SEC.gov

17 equity issuances filed in the last 30 days. Browse all equity issuances →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-292155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.